450 related articles for article (PubMed ID: 31746727)
1.
Swaminath S; Paul A; Pradhan A; Sebastian J; Nair RR; Ajitkumar P
Microbiology (Reading); 2020 Feb; 166(2):180-198. PubMed ID: 31746727
[TBL] [Abstract][Full Text] [Related]
2. De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells Formed against Antituberculosis Drugs In Vitro.
Sebastian J; Swaminath S; Nair RR; Jakkala K; Pradhan A; Ajitkumar P
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895008
[TBL] [Abstract][Full Text] [Related]
3. Unique Mode of Cell Division by the Mycobacterial Genetic Resister Clones Emerging
Jakkala K; Paul A; Pradhan A; Nair RR; Sharan D; Swaminath S; Ajitkumar P
mSphere; 2020 Nov; 5(6):. PubMed ID: 33208519
[TBL] [Abstract][Full Text] [Related]
4.
Paul A; Nair RR; Jakkala K; Ajitkumar P
Int J Mycobacteriol; 2022; 11(2):150-158. PubMed ID: 35775547
[TBL] [Abstract][Full Text] [Related]
5. Elevated Levels of Three Reactive Oxygen Species and Fe(II) in the Antibiotic-Surviving Population of Mycobacteria Facilitate
Paul A; Nair RR; Jakkala K; Pradhan A; Ajitkumar P
Antimicrob Agents Chemother; 2022 May; 66(5):e0228521. PubMed ID: 35435709
[TBL] [Abstract][Full Text] [Related]
6. [Establishment and drug susceptibility test of isoniazid resistant Mycobacterium smegmatis].
Jia PP; Zhao LL; Li XY; Zhang Q; Liu ZL; Wang X; Yu LY; Zhao LX; Cen S
Yao Xue Xue Bao; 2011 Apr; 46(4):377-82. PubMed ID: 21751489
[TBL] [Abstract][Full Text] [Related]
7. The Mycobacterial Efflux Pump EfpA Can Induce High Drug Tolerance to Many Antituberculosis Drugs, Including Moxifloxacin, in Mycobacterium smegmatis.
Rai D; Mehra S
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0026221. PubMed ID: 34424047
[TBL] [Abstract][Full Text] [Related]
8. Application of a microcalorimetric method for determining drug susceptibility in mycobacterium species.
Howell M; Wirz D; Daniels AU; Braissant O
J Clin Microbiol; 2012 Jan; 50(1):16-20. PubMed ID: 22090404
[TBL] [Abstract][Full Text] [Related]
9. Double mutation in DNA gyrase confers moxifloxacin resistance and decreased fitness of Mycobacterium smegmatis.
Luo T; Yuan J; Peng X; Yang G; Mi Y; Sun C; Wang C; Zhang C; Bao L
J Antimicrob Chemother; 2017 Jul; 72(7):1893-1900. PubMed ID: 28387828
[TBL] [Abstract][Full Text] [Related]
10. Potentiating the Anti-Tuberculosis Efficacy of Peptide Nucleic Acids through Combinations with Permeabilizing Drugs.
Cotta KB; Ghosh S; Mehra S
Microbiol Spectr; 2022 Feb; 10(1):e0126221. PubMed ID: 35171048
[TBL] [Abstract][Full Text] [Related]
11. Growth and division mechanisms by which genetic resisters emerge from the rifampicin-surviving population of differentially antibiotic-susceptible mycobacterial subpopulations.
Jakkala K; Paul A; Nair RR; Swaminath S; Pradhan A; Ajitkumar P
Int J Mycobacteriol; 2022; 11(3):273-286. PubMed ID: 36260446
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents.
Lu T; Drlica K
J Antimicrob Chemother; 2003 Dec; 52(6):1025-8. PubMed ID: 14613961
[TBL] [Abstract][Full Text] [Related]
13. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.
Al-Mutairi NM; Ahmad S; Mokaddas E; Eldeen HS; Joseph S
BMC Infect Dis; 2019 Jan; 19(1):3. PubMed ID: 30606116
[TBL] [Abstract][Full Text] [Related]
14. Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait.
Ahmad S; Jaber AA; Mokaddas E
Tuberculosis (Edinb); 2007 Mar; 87(2):123-9. PubMed ID: 17289435
[TBL] [Abstract][Full Text] [Related]
15. Lack of correlation between embB mutation and ethambutol MIC in Mycobacterium tuberculosis clinical isolates from China.
Shi R; Zhang J; Otomo K; Zhang G; Sugawara I
Antimicrob Agents Chemother; 2007 Dec; 51(12):4515-7. PubMed ID: 17846128
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous ethambutol & isoniazid resistance in clinical isolates of Mycobacterium tuberculosis.
Gupta P; Jadaun GP; Das R; Gupta UD; Srivastava K; Chauhan A; Sharma VD; Chauhan DS; Katoch VM
Indian J Med Res; 2006 Feb; 123(2):125-30. PubMed ID: 16575110
[TBL] [Abstract][Full Text] [Related]
17. Activity of Moxifloxacin against
Louie A; Duncanson B; Myrick J; Maynard M; Nole J; Brown D; Schmidt S; Neely M; Scanga CA; Peloquin C; Drusano GL
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249693
[TBL] [Abstract][Full Text] [Related]
18. Analysis of isoniazid, streptomycin and ethambutol resistance in Mycobacterium tuberculosis isolates from Morocco.
Chaoui I; Sabouni R; Kourout M; Jordaan AM; Lahlou O; Elouad R; Akrim M; Victor TC; El Mzibri M
J Infect Dev Ctries; 2009 May; 3(4):278-84. PubMed ID: 19759491
[TBL] [Abstract][Full Text] [Related]
19. Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.
Willby M; Sikes RD; Malik S; Metchock B; Posey JE
Antimicrob Agents Chemother; 2015 Sep; 59(9):5427-34. PubMed ID: 26100699
[TBL] [Abstract][Full Text] [Related]
20. Effect of Moxifloxacin plus Pretomanid against
de Miranda Silva C; Hajihosseini A; Myrick J; Nole J; Louie A; Schmidt S; Drusano GL
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
